– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed…
100% of patients treated with CTA313 achieved an SRI-4 response, with half achieving remission May 14, 2026 11:43 ET |…
The company is recognized for its innovation, scientific expertise, and customer-centric clinical development model in the global biotechnology CRO marketSAN…
Advancing Climate Action, Governance Excellence, and Global Scientific ImpactPISCATAWAY, N.J., April 14, 2026 /PRNewswire/ -- GenScript Biotech Corporation today announced its…
April 02, 2026 08:00 ET | Source: Tvardi Therapeutics HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”)…
BASEL, Switzerland, March 23, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotech focused on reprogramming the immune system with…
Group PerformanceRevenue: US$959.5 million, +61.4% year-on-yearGross profit: US$553.2 million, +103.3% year-on-yearAdjusted net profit: US$230.3 million, +285.0% year-on-yearBusiness Units' PerformanceGenScript Life…
Strategic investment reinforces Europe as a core pillar of GenScript's global R&D and production network, following recent U.S. facility expansion.DELFT, Netherlands, March…
Dr. Thomas L. F. Montgomery Andresen joins from T-Cypher BioFollows breakthrough non-human primate data demonstrating deep B-cell depletion without cytokine…
March 10, 2026 08:05 ET | Source: NKGen Biotech, Inc. SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen…